AstraZeneca (NASDAQ:AZN) Posts Earnings Results

AstraZeneca (NASDAQ:AZN) issued its quarterly earnings results on Tuesday. The company reported $1.04 EPS for the quarter, topping analysts’ consensus estimates of $1.01 by $0.03, Zacks reports. AstraZeneca had a return on equity of 30.41% and a net margin of 12.68%. The firm had revenue of $13.57 billion for the quarter, compared to analysts’ expectations of $13.08 billion. During the same period in the previous year, the firm posted $0.87 EPS. The business’s revenue for the quarter was up 18.0% compared to the same quarter last year.

AstraZeneca Price Performance

AZN traded up $0.58 during trading hours on Thursday, hitting $65.87. The company’s stock had a trading volume of 4,060,486 shares, compared to its average volume of 5,238,996. AstraZeneca has a 12 month low of $60.47 and a 12 month high of $87.68. The company has a current ratio of 0.89, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. The business’s 50-day moving average price is $75.79 and its 200-day moving average price is $78.38. The stock has a market cap of $204.24 billion, a price-to-earnings ratio of 31.24, a P/E/G ratio of 1.21 and a beta of 0.47.

Analysts Set New Price Targets

AZN has been the topic of a number of recent research reports. TD Cowen increased their target price on AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a report on Monday, August 12th. Erste Group Bank upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. Finally, Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $89.75.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.